Investigational Drug Information for Marizomib
✉ Email this page to a colleague
What is the drug development status for Marizomib?
Marizomib is an investigational drug.
There have been 12 clinical trials for Marizomib.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 26th 2018.
The most common disease conditions in clinical trials are Glioma, Neoplasms, Plasma Cell, and Glioblastoma. The leading clinical trial sponsors are Celgene, Triphase Research and Development I Corporation, and Triphase.
There are four hundred and twenty-four US patents protecting this investigational drug and zero international patents.
Summary for Marizomib
| US Patents | 424 |
| International Patents | 5,161 |
| US Patent Applications | 2,172 |
| WIPO Patent Applications | 1,208 |
| Japanese Patent Applications | 417 |
| Clinical Trial Progress | Phase 2 (2018-07-26) |
| Vendors | 29 |
Recent Clinical Trials for Marizomib
| Title | Sponsor | Phase |
|---|---|---|
| Marizomib Central Nervous System (CNS) | Bristol-Myers Squibb | Phase 2 |
| Marizomib Central Nervous System (CNS) | Dana-Farber Cancer Institute | Phase 2 |
| Phase I Study of Marizomib + Panobinostat for Children With DIPG | Celgene | Phase 1 |
Clinical Trial Summary for Marizomib
Top disease conditions for Marizomib
Top clinical trial sponsors for Marizomib
US Patents for Marizomib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Marizomib | ⤷ Sign Up | Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity | The University of North Carolina at Chapel Hill (Chapel Hill, NC) | ⤷ Sign Up |
| Marizomib | ⤷ Sign Up | Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells | Selecta Biosciences, Inc. (Watertown, MA) | ⤷ Sign Up |
| Marizomib | ⤷ Sign Up | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | ⤷ Sign Up |
| Marizomib | ⤷ Sign Up | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor | Pharmacyclics LLC (Sunnyvale, CA) | ⤷ Sign Up |
| Marizomib | ⤷ Sign Up | Methods and compositions for inhibition of Ras | ARAXES PHARMA LLC (San Diego, CA) | ⤷ Sign Up |
| Marizomib | ⤷ Sign Up | Anti-CS1 antibodies and antibody drug conjugates | AbbVie Biotherapeutics Inc. (Redwood City, CA) | ⤷ Sign Up |
| Marizomib | ⤷ Sign Up | Anti-tigit antibodies and methods of use | Genentech, Inc. (South San Francisco, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Marizomib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Marizomib | Australia | AU2015244171 | 2034-04-11 | ⤷ Sign Up |
| Marizomib | Australia | AU2015244179 | 2034-04-11 | ⤷ Sign Up |
| Marizomib | Canada | CA2945128 | 2034-04-11 | ⤷ Sign Up |
| Marizomib | Canada | CA2945129 | 2034-04-11 | ⤷ Sign Up |
| Marizomib | China | CN106414451 | 2034-04-11 | ⤷ Sign Up |
| Marizomib | China | CN106459063 | 2034-04-11 | ⤷ Sign Up |
| Marizomib | European Patent Office | EP3129377 | 2034-04-11 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
